When the US Food and Drug Administration approves cancer drugs based on response rate (RR) (ie, the percentage of patients whose cancer shrinks beyond an arbitrary threshold), what is the RR?
In this review of 85 cancer drug indications approved on the basis of RR, the median RR was 41%. Of the 85 approvals, 14 (16%) had RR less than 20%, 28 (33%) had an RR less than 30%, and 40 (47%) had an RR less than 40%.
Many cancer drugs are approved on the basis of low or modest RRs, typically in single-arm studies.
Approximately one-third of cancer drugs are approved based on response rate (RR)—the percentage of patients whose tumors shrink beyond an arbitrary threshold—typically assessed in a single-arm study.
To characterize RR end points used by the US Food and Drug Administration (FDA) for cancer drug approval.
Design, Setting, and Participants
A retrospective review of FDA-approved drug indications in oncology from 2006 to 2018.
Data related to cancer type, line of therapy (first-line, second-line, or third-or-later-line treatment for advanced/metastatic disease), type of FDA approval pathway, trial design, sample size, and level of innovation were extracted.
Main Outcomes and Measures
The primary outcome was the RR used as the basis for FDA approval. The secondary outcome was rate of complete response.
Eighty-five indications for 59 cancer drugs were identified, 32 (38%) received regular approval, and 53 (62%) were granted accelerated approval. Twenty-nine (55%) accelerated approvals were later converted to regular approval. Of these, 6 (21%) approvals showed overall survival benefit, 16 (55%) later established progression-free survival benefit, and 7 (24%) continued to use RR but gained regular approval. The median RR among the 85 indications was 41% (interquartile range [IQR], 27%-58%). Among them, 14 of 85 (16%) had an RR less than 20%, 28 of 85 (33%) had an RR less than 30%, and 40 of 85 (47%) had an RR less than 40%. The median complete RR for 81 participants was 6% (IQR, 2%-22%). The median sample size among studies leading to approval was 117 (IQR, 76-182; range, 18-1052 participants). Drugs with accelerated approval pending confirmatory data had lower RR compared with drugs that have completed most postmarketing efficacy requirements (median, 28%; IQR, 15%-50% vs median, 42%; IQR, 31%-58%; P = .02).
Conclusions and Relevance
Many cancer drugs approved on the basis of response rate offer numerically low or modest response rates. Most premarket studies accrue more than 100 patients. Some of these drugs could potentially be tested in premarket randomized clinical trials measuring directly end points that demonstrate clinical benefit.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Chen EY, Raghunathan V, Prasad V. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. JAMA Intern Med. Published online May 28, 2019. doi:10.1001/jamainternmed.2019.0583
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: